ASPHF (Ascentage Pharma Group International) Beneish M-Score: 0.65 (As of Jun. 25, 2026)


ASPHF Ascentage Pharma Group International ASPHF
71 GF Score
Price $4.53
GF Value $6.61
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Ascentage Pharma Group International Beneish M-Score?

Ascentage Pharma Group International ASPHF -3.51% 71 Beneish M-Score is 0.65 as of Jun. 25, 2026. GuruFocus rates ASPHF with a GF Score™ of 71/100 and a GF Value™ of $6.61 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 831 Biotechnology companies, Ascentage Pharma Group International ranks worse than 85.56% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 0.65 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Ascentage Pharma Group International's Beneish M-Score or its related term are showing as below:

ASPHF' s Beneish M-Score Range Over the Past 10 Years
Min: -3.71   Med: -0.51   Max: 2.12
Current: 0.65

During the past 10 years, the highest Beneish M-Score of Ascentage Pharma Group International was 2.12. The lowest was -3.71. And the median was -0.51.


Ascentage Pharma Group International Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Ascentage Pharma Group International's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascentage Pharma Group International Beneish M-Score Chart

Ascentage Pharma Group International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.32 2.12 -1.70 -0.70 0.65

Ascentage Pharma Group International Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.70 0.00 -0.70 0.00 0.65

ASPHF vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Ascentage Pharma Group International's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascentage Pharma Group International Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascentage Pharma Group International's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Ascentage Pharma Group International's Beneish M-Score falls into.


ASPHF
71GF Score
Ascentage Pharma Group International ASPHF
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascentage Pharma Group International Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Ascentage Pharma Group International for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 5.1918+0.528 * 1.0608+0.404 * 0.5282+0.892 * 0.6052+0.115 * 0.9875
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 2.6746+4.679 * -0.000562-0.327 * 0.7712
=0.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was $42.76 Mil.
Revenue was $81.51 Mil.
Gross Profit was $74.57 Mil.
Total Current Assets was $418.02 Mil.
Total Assets was $562.75 Mil.
Property, Plant and Equipment(Net PPE) was $117.74 Mil.
Depreciation, Depletion and Amortization(DDA) was $12.28 Mil.
Selling, General, & Admin. Expense(SGA) was $85.18 Mil.
Total Current Liabilities was $233.33 Mil.
Long-Term Debt & Capital Lease Obligation was $107.51 Mil.
Net Income was $-176.45 Mil.
Gross Profit was $-9.43 Mil.
Cash Flow from Operations was $-166.70 Mil.
Total Receivables was $13.61 Mil.
Revenue was $134.69 Mil.
Gross Profit was $130.70 Mil.
Total Current Assets was $202.48 Mil.
Total Assets was $359.56 Mil.
Property, Plant and Equipment(Net PPE) was $124.42 Mil.
Depreciation, Depletion and Amortization(DDA) was $12.80 Mil.
Selling, General, & Admin. Expense(SGA) was $52.62 Mil.
Total Current Liabilities was $160.23 Mil.
Long-Term Debt & Capital Lease Obligation was $122.16 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(42.756 / 81.514) / (13.608 / 134.692)
=0.524523 / 0.10103
=5.1918

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(130.697 / 134.692) / (74.566 / 81.514)
=0.97034 / 0.914763
=1.0608

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (418.016 + 117.737) / 562.752) / (1 - (202.475 + 124.419) / 359.555)
=0.047977 / 0.090837
=0.5282

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=81.514 / 134.692
=0.6052

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(12.797 / (12.797 + 124.419)) / (12.279 / (12.279 + 117.737))
=0.093262 / 0.094442
=0.9875

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(85.177 / 81.514) / (52.622 / 134.692)
=1.044937 / 0.390684
=2.6746

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((107.513 + 233.327) / 562.752) / ((122.163 + 160.233) / 359.555)
=0.605666 / 0.785404
=0.7712

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-176.449 - -9.429 - -166.704) / 562.752
=-0.000562

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Ascentage Pharma Group International has a M-score of 0.65 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 0.65 mean?
Ascentage Pharma Group International (ASPHF) has a Beneish M-Score of 0.65 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Ascentage Pharma Group International and its competitors. According to the industry distribution chart, Ascentage Pharma Group International ranks #711 out of 831 companies in the Biotechnology industry, placing it in the top 85.6%.
Is Ascentage Pharma Group International's Beneish M-Score too high?
Ascentage Pharma Group International's current Beneish M-Score is 0.65. Based on the distribution chart, Ascentage Pharma Group International ranks #711 out of 831 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ascentage Pharma Group International has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ascentage Pharma Group International's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascentage Pharma Group International ranks #711 out of 831 companies for Beneish M-Score. This places Ascentage Pharma Group International in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Ascentage Pharma Group International and its competitors. Ascentage Pharma Group International's current Beneish M-Score is 0.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascentage Pharma Group International stock overvalued right now?
Based on GuruFocus' analysis, Ascentage Pharma Group International (ASPHF) is currently considered Possible Value Trap. The stock's GF Value™ is $6.61, compared to a current price of $4.53 — trading 31.5% below its estimated fair value. The current Beneish M-Score is 0.65. Ascentage Pharma Group International's overall GF Score™ is 71/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Ascentage Pharma Group International (ASPHF), the current Beneish M-Score is 0.65 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ascentage Pharma Group International (ASPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Ascentage Pharma Group International stock appears to be undervalued. The current stock price of $4.53 is trading 31.5% below its estimated GF Value™ of $6.61. GuruFocus considers Ascentage Pharma Group International to be Possible Value Trap.

Key valuation signals for ASPHF:

  • Beneish M-Score: 0.65
  • GF Value™: $6.61 vs. price of $4.53 (31.5% below fair value)
  • GF Score™: 71/100 with 7 warning signs

No single metric tells the full story. See the ASPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ascentage Pharma Group International Business Description

Address 68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
71GF Score

Get the complete analysis for ASPHF

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.53
Price
$6.61
GF Value